TherapeuticsMD, Inc.
951 Broken Sound Parkway NW
Suite #320
Boca Raton
Florida
33487
United States
Tel: 561-961-1911
Website: http://www.therapeuticsmd.com/
Email: info@therapeuticsmd.com
244 articles about TherapeuticsMD, Inc.
-
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
3/10/2022
TherapeuticsMD, Inc. today reported financial results for the fourth quarter ended December 31, 2021.
-
U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®
12/10/2021
TherapeuticsMD, Inc. (NASDAQ:TXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that the FDA determined that it could not approve revisions to certain manufacturing testing limits for ANNOVERA through the sNDA previously submitted by the Company.
-
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
12/8/2021
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of New York LLC (collectively “Amneal”).
-
TherapeuticsMD Announces Third Quarter 2021 Financial Results
11/11/2021
TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the third quarter ended September 30, 2021.
-
TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021
10/27/2021
TherapeuticsMD, Inc. today announced that it will report its third quarter 2021 financial results on Thursday, November 11, 2021, before the opening of the U.S. financial markets.
-
TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer
10/15/2021
TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, announced the appointment of Mark Glickman as the Company’s Chief Business Officer.
-
TherapeuticsMD Announces Appointment of Hugh O’Dowd as President
8/9/2021
TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, announced the appointment of Hugh O’Dowd as President.
-
TherapeuticsMD Announces Second Quarter 2021 Financial Results
8/4/2021
TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, reported financial results for the second quarter ended June 30, 2021.
-
TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021
7/26/2021
TherapeuticsMD, Inc. today announced that it will report its second quarter 2021 financial results on Wednesday, August 4, 2021, before the opening of the U.S. financial markets.
-
TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA
5/25/2021
TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, announced that the Company submitted a supplemental New Drug Application for BIJUVA capsules, 0.5 mg/100 mg, to the U.S. Food and Drug Administration.
-
TherapeuticsMD Announces First Quarter 2021 Financial Results
5/6/2021
- 1Q21 total net revenue increased to $19.9 million - - 1Q21 total net product revenue increased 60% to $19.6 million compared to 1Q20 - - ANNOVERA prescriptions continue to grow with increasing consumer support and acceptance - - Further strengthened ANNOVERA® patent family through June 2039 –
-
TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting
5/3/2021
TherapeuticsMD Announces Poster Presentation of ANNOVERA ® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting -Poster included analyses of ANNOVERA Phase 3 menstrual bleeding profile data-
-
TherapeuticsMD and Theramex Announce the Approval of BIJUVE® Capsules Indicated for Hormone Replacement Therapy in the United Kingdom and Under the Trade Name BIJUVA® in Belgium
4/8/2021
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, and Theramex, a dedicated women’s health company, announced that BIJUVE® has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the United Kingdom and, from the Federal Agency for Medicines and Health Products (FAMHP) for use in Belgium under BIJUVA
-
TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results
3/2/2021
- Full-year 2020 total net product revenue increased 84% to $62.9 million compared to 2019 - - 4Q20 total net product revenue increased 30% to $22.6 million compared to 3Q20 - - ANNOVERA ® net product revenue increased 42% for 4Q20 compared to 3Q20 - - Financing Agreement amended to update minimum net revenue covenants for remainder of loan; Company to pay down $50 million in debt -
-
TherapeuticsMD Announces Participation in Upcoming Investor Conferences
3/1/2021
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate at the following investor conferences:
-
TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock
2/11/2021
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 59.5 million shares of its common stock for gross proceeds of $110 million
-
TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
2/10/2021
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock.
-
TherapeuticsMD Announces Participation in the Stifel 2020 Virtual Healthcare Conference
11/13/2020
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Stifel 2020 Virtual Healthcare Conference. Details for the presentation include: Conference Stifel 2020 Virtual Healthcare Conference Date Tuesday, November 17, 2020 Time 9:20 a.m. Eastern time
-
TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock
11/10/2020
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock for gross proceeds of $30 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by TherapeuticsMD.
-
TherapeuticsMD® Announces Third Quarter 2020 Financial Results
11/9/2020
TherapeuticsMD, Inc., an innovative, leading women’s healthcare company, reported financial results for the third quarter ended September 30, 2020.